CORT Stock — Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (CORT)

Updated October 16, 2026.

CORT is a Stock. Total return is 800.7% over the past 22.5 years, 115.0 points behind SPY at 915.7%.

Corcept Therapeutics is a biopharmaceutical company focused on discovering and developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company markets Korlym for treating hyperglycemia in patients with endogenous Cushing's syndrome, and maintains a pipeline of selective cortisol modulators in development for conditions including metabolic dysfunction-associated steatohepatitis and amyotrophic lateral sclerosis. The company does not currently have an established distribution program, making it oriented toward growth-focused investors rather than those seeking current income.

CORT performance versus SPY

Price and return data through 2026-10-16.

Total return is 800.7% over the past 22.5 years, 115.0 points behind SPY at 915.7%. Over the past year its total return — price change plus distributions reinvested — is 38.6%. Its deepest 1-year drawdown was 63.5%.

CORT key facts

Asset type

Stock

Asset class

Equity

Inception date

04/14/2004

Distribution frequency

None

Last close

$110.16 (as of 2026-10-16)

Market cap

$11,908,119,414

Average volume

849640.0

Beta

0.401

Payout ratio

0.0%

P/E ratio

256.19

Forward P/E

19.305

EPS

$0.43

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CORT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 63.5%.

Who may consider CORT — and who may not

It is a weaker fit for investors who need monthly cash flow (CORT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CORT

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions